Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Exploring SNP-SNP interactions and colon cancer risk using polymorphism interaction analysis.

Julie E Goodman1, Leah E Mechanic, Brian T Luke

  • 1Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, MD 20892, USA.

International Journal of Cancer
|October 12, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The urinary-metabolite-based lung cancer index (uLCI): an interpretable machine-learning risk model for early-stage disease.

medRxiv : the preprint server for health sciences·2026
Same author

The senescence-inhibitory p53 isoform Δ133p53α represses the proinflammatory chemokine CXCL10 in progeria model mice and naturally aged mice.

bioRxiv : the preprint server for biology·2026
Same author

Interpretation of the IARC quantitative bias analysis of talc and ovarian cancer.

Global epidemiology·2026
Same author

Senescence-inhibitory Δ133p53α counteracts accelerated ageing and mortality.

bioRxiv : the preprint server for biology·2026
Same author

Urinary pesticide profiles and liver disease risk in Thailand: a machine-learning risk-prediction model.

medRxiv : the preprint server for health sciences·2026
Same author

Urinary Metabolites and Survival in Malignant Mesothelioma.

medRxiv : the preprint server for health sciences·2025

This study introduces polymorphism interaction analysis (PIA) to explore gene variations linked to colon cancer. PIA identified glutathione-S-transferase T1 (GSTT1) null polymorphisms interacting with TP53 and CASP8 as key predictors of colon cancer risk.

Area of Science:

  • Genetics and Genomics
  • Cancer Research
  • Bioinformatics

Background:

  • Colon cancer risk is influenced by single nucleotide polymorphisms (SNPs) in various genes.
  • Few studies have investigated concurrent SNP-SNP interactions for colon cancer prediction.
  • Understanding these interactions is crucial for personalized risk assessment.

Purpose of the Study:

  • To develop and apply a novel method, polymorphism interaction analysis (PIA), for evaluating SNP-SNP interactions in colon cancer.
  • To identify specific SNPs and their combinations that predict colon cancer risk in males.
  • To explore potential interactions between glutathione-S-transferase T1 (GSTT1) and other genetic polymorphisms.

Main Methods:

  • Developed and utilized polymorphism interaction analysis (PIA) to examine all possible combinations of 94 SNPs in 216 male colon cancer cases and 255 male controls.

Related Experiment Videos

  • Employed dual cross-validation functions within PIA to minimize false positives.
  • Validated significant SNP interactions using logistic regression analysis.

    • Main Results:

    • PIA identified GSTT1 null polymorphisms as a significant predictor of colon cancer.
    • Novel polymorphisms in inflammation and hormone metabolism pathways were found to predict cancer risk, individually or combined.
    • Interactions between GSTT1 null polymorphism and TP53 (Arg72Pro) or CASP8 (Asp302His) polymorphisms significantly altered colon cancer risk (p(interaction) < 0.02).

    Conclusions:

    • Polymorphism interaction analysis (PIA) is a valid method for identifying potential SNP-SNP interactions relevant to colon cancer.
    • The study highlights the combined effect of GSTT1, TP53, and CASP8 polymorphisms on colon cancer risk.
    • These findings suggest new avenues for investigating genetic predisposition to colon cancer and warrant further validation.